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Introduction {#sec001}
============

Ocular dryness and xerostomia are common symptoms in the population for which many patients seek medical help for their condition \[[@pone.0155214.ref001]\]. According to the dry eye workshop (2007) "Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface" \[[@pone.0155214.ref002]\]. Systemic diseases (Sjögren's syndrome \[SS\] and diabetes), as well as local (contact lens wear) and environmental (low humidity) factors, can cause dry eye disease (DED) \[[@pone.0155214.ref002]\]. The prevalence of DED is estimated to 5--30% in the population above 50 years of age \[[@pone.0155214.ref002]\]. Dependent on etiology, DED is divided in two major categories; an aqueous deficient and an evaporative type. These two categories do not mutually exclude each other as they can act in combination.

Xerostomia is defined as a subjective feeling of dry mouth. Patients with this condition may report substantial discomfort and reduced quality of life \[[@pone.0155214.ref003]\]. Some complain of difficulties with swallowing, speaking, burning mouth and wearing dentures \[[@pone.0155214.ref004]\]. The term salivary dysfunction is herein used to indicate patients with xerostomia and/or patients whose saliva flow rate is measurably reduced \[[@pone.0155214.ref005]\]. Since saliva has many important properties in the oral cavity, dysfunction may cause devastating oral effects, such as caries, erosions and infections \[[@pone.0155214.ref006]\].

Symptoms and clinical findings do not always correspond, as patients with xerostomia do not always have reduced salivary output \[[@pone.0155214.ref007]\]. The same lack of relation is also found among patients with ocular dryness, whose clinical signs of DED are not always detected \[[@pone.0155214.ref008]--[@pone.0155214.ref010]\]. The presence of xerostomia and ocular dryness has traditionally been included among the diagnostic criteria for SS \[[@pone.0155214.ref011], [@pone.0155214.ref012]\]. However, a new revision of the diagnostic criteria for SS is suggested, since ocular dryness and xerostomia are common conditions and individually have low specificity for diagnosing SS \[[@pone.0155214.ref001], [@pone.0155214.ref013]\].

Several factors and conditions can induce xerostomia. Use of prescription drugs is one of the most common causes \[[@pone.0155214.ref014]\]. In addition to SS, a wide variety of autoimmune and endocrine disorders are associated with xerostomia \[[@pone.0155214.ref015]\]. These diseases include diabetes, rheumatoid arthritis, systemic lupus erythematosus and thyroid disease, even when they are not co-occurring with SS \[[@pone.0155214.ref016]\]. All of these conditions are also associated with DED \[[@pone.0155214.ref002], [@pone.0155214.ref017]--[@pone.0155214.ref019]\].

Schein *et al*. investigated the prevalence of xerostomia and/or dry eyes in a population based study that included 2481 individuals between 65 and 85 years \[[@pone.0155214.ref020]\]. Akpek and associates evaluated the number of patients with an underlying systemic disease in a cohort of DED patients, but they did not report the prevalence of xerostomia \[[@pone.0155214.ref021]\]. Neither the study by Schein *et al*. \[[@pone.0155214.ref020]\] nor the one by Akpek and associates \[[@pone.0155214.ref021]\] investigated if xerostomia is associated with the degree of severity of symptoms and signs of DED. If such an association can be found, xerostomia might be a more useful anamnestic marker when examining DED patients than previously considered.

In this study, we assessed the prevalence of xerostomia in 318 patients with DED from 15 to 91 years of age. We compared patients with and without xerostomia to explore whether they differed in the degree of symptoms and signs of DED.

Materials and Methods {#sec002}
=====================

Patients {#sec003}
--------

The study was conducted in accordance with the Declaration of Helsinki. Three hundred and eighteen patients with dry eyes, diagnosed by an ophthalmologist at the Norwegian Dry Eye Clinic between August 2012 and October 2013, that did not have missing data on any of the study parameters, were included. The patients underwent a comprehensive ophthalmological work-up and completed self-report questionnaires on symptoms of ocular dryness (Ocular Surface Disease Index \[OSDI\] and McMonnies Dry Eye Questionnaire) and the SS questionnaire. The questionnaires were distributed and collected at the Norwegian Dry Eye Clinic by the examining ophthalmologist, who also co-authored. The data from the questionnaires were then made anonymous by the same ophthalmologist, and included in the Norwegian Dry Eye Clinic databank. All examinations were carried out at the same clinic. The use of the data for the study from the Norwegian Dry Eye Clinic has been reviewed by The Regional Committee for Medical & Health Research Ethics, Section C, South East Norway (REC). REC found the research project "*Evaluation of data from the Norwegian Dry Eye Clinic*" to be outside the remit of the Act on Medical and Health Research (2008) and therefore can be implemented without its approval. A REC letter of exemption has been provided.

Ophthalmological Work-Up {#sec004}
------------------------

The same ophthalmologist examined all patients during normal working hours between 9 AM and 4 PM. The ophthalmological examination included assessment of ocular staining (lissamine green and fluorescein) \[[@pone.0155214.ref022]\], tear film break-up time (TFBUT) \[[@pone.0155214.ref023], [@pone.0155214.ref024]\], Schirmer I \[[@pone.0155214.ref018]\], meibum expressibility \[[@pone.0155214.ref025]\], meibum quality \[[@pone.0155214.ref025]\], ocular protection index (OPI) \[[@pone.0155214.ref024]\], and dry eye severity level (DESL) ([Table 1](#pone.0155214.t001){ref-type="table"}) \[[@pone.0155214.ref018]\]. The mean scores from both eyes of each subject were used for analyses. Measurements were performed on patients irrespective of degree of dry eye severity.

10.1371/journal.pone.0155214.t001

###### Ophthalmological Work-up.

![](pone.0155214.t001){#pone.0155214.t001g}

  Parameter                                                                                Scoring Method                                                                                                                                                                                                                               Pathological Score
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  **Dry eye severity level \[[@pone.0155214.ref002]\]**                                    Four-level composite score based on ocular discomfort, visual disturbance, conjunctival injection, conjunctival/corneal staining, other signs of corneal/tear pathology, signs of lid/meibomian gland pathology, TFBUT and Schirmer score.   \>0
  **Tear film break-up time (TFBUT) \[[@pone.0155214.ref023], [@pone.0155214.ref024]\]**   The interval in seconds between the last complete blink and the first appearance of a dry spot, or disruption in the tear film following instillation of fluorescein.                                                                        ≤10
  **Ocular protection index \[[@pone.0155214.ref024]\]**                                   TFBUT divided by the interblink interval (mean time in seconds between two complete blinks).                                                                                                                                                 \<1
  **Schirmer I \[[@pone.0155214.ref018]\]**                                                Paper test strips are inserted in the lower lateral third of the conjunctival sac and the eyes are closed for 5 minutes. The wetting of the paper strip is then measured in millimeters.                                                     ≤10
  **Staining \[[@pone.0155214.ref022]\]**                                                  Following fluorescein instillation the staining scores of the exposed cornea and interpalpebral conjunctiva are summarized using the Oxford grading scheme (range: 0--15).                                                                   \>0
  **Meibum expressibility \[[@pone.0155214.ref025]\]**                                     Five glands in the lower lid are evaluated according to the number of expressible glands: 0, all glands; 1, three to four glands; 2, one to two glands; and 3, no glands (score range: 0 to 3).                                              \>0
  **Meibum quality \[[@pone.0155214.ref025]\]**                                            Eight glands from the central third of the lower lid are evaluated on a scale of 0 to 3 for each gland: 0, clear; 1, cloudy; 2, cloudy with debris (granular); and 3, thick, toothpaste-like (total score range: 0--24).                     \>0

Self-Report Questionnaires {#sec005}
--------------------------

The OSDI questionnaire included 12 items regarding symptoms of ocular dryness ([Table 2](#pone.0155214.t002){ref-type="table"}) \[[@pone.0155214.ref026]\]. The SS questionnaire incorporated six items on ocular and oral symptoms by the revised criteria from the American- European consensus group \[[@pone.0155214.ref012]\]. In the current study, patients answering "yes" to the question "have you had daily sensation of dry mouth the last three months" in the SS questionnaire were defined as suffering from xerostomia. For each patient the number of different systemic prescription drug categories used, as defined by the McMonnies Dry Eye Questionnaire, was summarized ([Table 3](#pone.0155214.t003){ref-type="table"}).

10.1371/journal.pone.0155214.t002

###### Ocular Surface Disease Index.
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  -----------------------------------------------------------------------------------------------------
  *Have you experienced any of the following during the last week*?
          1. Eyes that are sensitive to light?
          2. Eyes that feel gritty?
          3. Painful or sore eyes?
          4. Blurred vision?
          5. Poor vision?
  *Have problems with your eyes limited you in performing any of the following during the last week*?
          6. Reading?
          7. Driving at night?
          8. Working with computer screens?
          9. Watching TV?
  *Have your eyes felt uncomfortable in any of the following situations during the last week*?
          10. Windy conditions?
          11. Places or areas with low humidity (very dry)?
          12. Areas that are air-conditioned?
  -----------------------------------------------------------------------------------------------------

10.1371/journal.pone.0155214.t003

###### Prescription drug categories used in xerostomia and non-xerostomia patients.

![](pone.0155214.t003){#pone.0155214.t003g}

  Prescription drug categories[^1^](#t003fn002){ref-type="table-fn"}   Xerostomia[^2^](#t003fn003){ref-type="table-fn"} (n = 72)   Non-xerostomia (n = 246)   XerostomiaOR (95% CI)         *P*-value[^3^](#t003fn004){ref-type="table-fn"}
  -------------------------------------------------------------------- ----------------------------------------------------------- -------------------------- ----------------------------- -------------------------------------------------
  Antihistamines                                                       22 (31)                                                     27 (11)                    ***2*.*8 (1*.*4--5*.*6)***    ***0*.*004***
  Diuretics                                                            7 (10)                                                      5 (2)                      ***4*.*0 (1*.*1--14*.*2)***   ***0*.*033***
  Antidepressants                                                      12 (17)                                                     13 (5)                     2.1 (0.8--5.2)                0.109
  Anxiolytics                                                          12 (17)                                                     26 (11)                    0.8 (0.3--1.7)                0.492
  Medications against urge incontinence                                3 (4)                                                       3 (1)                      1.7 (0.3--9.6)                0.529
  Oral contraceptives                                                  1 (2)                                                       9 (8)                      0.5 (0.1--4.6)                0.550[^4^](#t003fn005){ref-type="table-fn"}
  Antihypertensives                                                    8 (11)                                                      11 (5)                     1.3 (0.5--3.8)                0.615
  Antitussives                                                         8 (11)                                                      20 (8)                     1.3 (0.5--3.2)                0.625
  Medications against dyspepsia and gastro-esophageal reflux           5 (7)                                                       10 (4)                     1.2 (0.4--4.1)                0.771
  Anti-Parkinsonian medications                                        1 (1)                                                       1 (0)                      1.2 (0.1--20.4)               0.903
  Hormone replacement therapy                                          7 (12)                                                      9 (8)                      1.1 (0.4--3.2)                0.908[^4^](#t003fn005){ref-type="table-fn"}
  Medications against chronic obstructive pulmonary disease            1 (1)                                                       1 (0)                      0.9 (0.1--14.8)               0.922
  Medications against benign prostatic hyperplasia                     0 (0)                                                       4 (3)                      0 (0)                         0.999[^5^](#t003fn006){ref-type="table-fn"}
  Medications against acne                                             0 (0)                                                       1 (0)                      0 (0)                         1.0
  Antipsychotics                                                       0 (0)                                                       0 (0)                      \-                            \-

OR = odds ratio; CI = confidence interval

^1^As defined by the McMonnies Dry Eye Questionnaire.

^2^Daily dry mouth for the last three months

^3^Logistic regression analysis adjusted for age and sex, unless otherwise stated.

^4^Analysed in female patients (n = 166) and adjusted for age.

^5^Analysed in male patients (n = 152) and adjusted for age.

Statistics {#sec006}
----------

Data are presented as mean ± standard deviation (SD). Chi-square test was performed when comparing differences in sex, prescription drug use and meibum expressibility between patients with and without xerostomia, whereas Student's t-test was used to compare the age of patients with and without xerostomia. The use of various systemic prescription drugs was compared between patients with and without xerostomia using logistic regression analysis with adjustment for age and sex. To assess the differences in OSDI and ocular signs between the patients with and without xerostomia, multivariate analysis of covariance (MANCOVA) was performed, adjusting for age, sex and the number of systemic prescription drugs used. A significance level of *P*\<0.05 was used throughout the study (SPSS ver. 21.0).

Results {#sec007}
=======

The majority of the patients (71%) were between 40 and 80 years of age, with a similar sex distribution across most age groups ([Fig 1A](#pone.0155214.g001){ref-type="fig"}). Xerostomia was confirmed by 72 of the 318 patients (23%). One hundred and sixty-six (52%) of the 318 patients were females and 152 (48%) were males. Seven of the 318 patients (2%) reported a previous SS diagnosis.

![Patient demographics.\
(**A**) Bar graph showing the age and sex distribution among 318 patients with dry eye disease consecutively included in the study. (**B**) Scatterplot showing the prevalence of xerostomia according to age in 318 dry eye disease patients.](pone.0155214.g001){#pone.0155214.g001}

Compared to those without xerostomia, patients reporting xerostomia were overrepresented by women (44% and 81% women, respectively; *P*\<0.001). Sixty-five percent of patients with xerostomia, in contrast to only 35% of patients without xerostomia, used at least one prescription drug (*P*\<0.021; adjusted for age and sex). The use of antihistamines and diuretics were more prevalent among xerostomia patients than among non-xerostomia patients (*P*\<0.05; adjusted for age and sex) ([Table 3](#pone.0155214.t003){ref-type="table"}). Patients with xerostomia (60 ± 15 years) were older than those without xerostomia (51 ± 17; *P*\<0.001) ([Fig 1B](#pone.0155214.g001){ref-type="fig"}).

Patients with xerostomia were compared with those without xerostomia on the presence of symptoms and signs of DED following adjustment for age, sex and the number of systemic prescription drugs used ([Table 4](#pone.0155214.t004){ref-type="table"}). After applying a threshold to separate those with normal meibum expressibility (all glands expressible, which equals a score of 0) from those with pathological meibum expressibility (not all glands expressible, which equals a score \>0) the Chi-square test was also used to investigate the association between xerostomia and meibum expressibility. Among the 72 patients with xerostomia 72% (52 patients) had pathological meibum expressibility, whereas among the 246 patients without xerostomia, only 53% (130 patients) had pathological meibum expressibility (*P* = 0.003). Thus, these results show that the xerostomia patients have a more severe meibum expressibility score and a lower prevalence of normal meibum expressibility.

10.1371/journal.pone.0155214.t004

###### Severity of Ocular Signs in Patients with/without Xerostomia.
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  Parameter                             Xerostomia[^1^](#t004fn001){ref-type="table-fn"}   Non-xerostomia   F              P-value[\*](#t004fn002){ref-type="table-fn"}
  ------------------------------------- -------------------------------------------------- ---------------- -------------- ----------------------------------------------
  Ocular surface disease index (OSDI)   19.0 ± 10.0                                        12.9 ± 8.0       ***20*.*2***   ***\<0*.*001***
  Dry eye severity level (DESL)         2.1 ± 0.5                                          2.0 ± 0.5        1.8            0.183
  Tear film break up time (TFBUT)       5.7 ± 3.6                                          6.5 ± 4.2        0.1            0.760
  Ocular protection index (OPI)         2.2 ± 1.8                                          2.5 ± 2.1        0.2            0.688
  Schirmer I                            13.4 ± 9.2                                         15.0 ± 9.0       2.2            0.141
  Staining                              1.8 ± 2.0                                          1.5 ± 1.9        0.9            0.356
  Meibum expressibility                 0.9 ± 0.7                                          0.7 ± 0.8        ***4*.*0***    ***0*.*046***
  Meibum quality                        5.4 ± 3.3                                          6.4 ± 4.8        0              0.867

^1^ Daily dry mouth for the last three months

\* Multivariate analyses of covariance with adjustment for age, sex and the number of systemic prescription drugs used.

Discussion {#sec008}
==========

In the current study, we found that 23% of the DED patients reported xerostomia, and that xerostomia patients, compared to those without xerostomia, reported a higher symptom load and had poorer meibum expressibility. Hence, these results could indicate that, in patients with DED, reporting xerostomia is a risk factor for more pronounced symptoms of dry eyes.

The prevalence of xerostomia varies between the population studied and depends on how xerostomia is defined in each study. This issue is elucidated by Hopcraft and Tan \[[@pone.0155214.ref027]\]. They found that the prevalence of xerostomia in population based studies varied between 10 to 46% \[[@pone.0155214.ref027]\]. A study by Schein *et al*. showed that ocular dryness *or* xerostomia were present often or all the time in 27% in a population-based study involving 2481 individuals between the ages of 65 to 85 years \[[@pone.0155214.ref020]\]. Only 4.4% reported to have concomitant ocular dryness *and* xerostomia \[[@pone.0155214.ref020]\]. In our study, 23% (33% of patients between 65 and 85 years) of the dry eye patients reported xerostomia. The Schein study \[[@pone.0155214.ref020]\], however, used a different definition of 'xerostomia' compared to the current study.

Schein *et al*. used a symptom-based definition of dry eyes. Their six-item dry eye questionnaire \[[@pone.0155214.ref028]\] included questions regarding the sensation of dry, gritty, red or burning eyes, as well as lash crusting and the experience of eyes getting stuck shut in the morning. Degree of symptomatic dry eyes in the current study was scored using the OSDI, which includes 12 validated questions for measuring the severity of DED ([Table 2](#pone.0155214.t002){ref-type="table"}) \[[@pone.0155214.ref029]\]. Whereas the questionnaire used by Schein *et al*. and the OSDI both include questions regarding symptoms directly associated with dry eyes, the latter also includes items on vision-related function. In addition to symptoms, the current study also included clinical tests to diagnose DED ([Table 1](#pone.0155214.t001){ref-type="table"}). Patients having a DESL of at least 1, as determined by the examining ophthalmologist, were defined as having DED. DESL is a four-level composite score based on symptoms and signs of dry eye ([Table 1](#pone.0155214.t001){ref-type="table"}).

In the current study, clinical tests were performed irrespective of the degree of dry eyes or any other known patient characteristics. Hence, missing data were assumed missing completely at random. Patients that did not have complete data sets were therefore excluded from the study by listwise deletion. Nevertheless, as patients with incomplete data sets were excluded a potential selection bias cannot be definitely ruled out.

Patients with xerostomia reported a significantly higher OSDI score than patients without xerostomia after adjusting for age, sex, and use of systemic prescription drugs. Interestingly, Alves *et al*. found that OSDI scores were higher in patients with SS, diabetes mellitus and thyroid disorder than control subjects \[[@pone.0155214.ref030]\]. All of these conditions are also associated with xerostomia \[[@pone.0155214.ref031], [@pone.0155214.ref032]\]. In contrast to our finding that xerostomia is related to the OSDI score, which is a subjective measure of ocular dryness, the correlation between hyposalivation and xerostomia has been reported to be weak \[[@pone.0155214.ref033]\]. Since we have controlled for several confounders in this study the association between xerostomia and OSDI could, therefore, be attributed partly to higher symptom awareness in some patients or an undiagnosed systemic disease aggravating both xerostomia and DED.

The female/male-ratio was approximately 1:1 in our study. This is somewhat unexpected since DED predominates among women \[[@pone.0155214.ref018]\]. In addition to ocular dryness, women more often report having xerostomia \[[@pone.0155214.ref027]\], which was also the case in the current study. Hormonal alterations in the levels of androgen and estrogen are suggested to be related to ocular dryness and xerostomia due to the worsening of these symptoms in postmenopausal women \[[@pone.0155214.ref034], [@pone.0155214.ref035]\].

Increasing age and the use of prescription drugs were associated with xerostomia in the present study, which is also in line with previous reports \[[@pone.0155214.ref027]\].

The increased prevalence of prescription drug use among patients with xerostomia compared to those without xerostomia was independent of age and sex. Aging of the salivary gland coincides with a reduction in the amount of acini and an increase in fat infiltration and fibrosis \[[@pone.0155214.ref036]\]. Although increasing age may be linked with xerostomia, the reserve capacity in the salivary glands seems to compensate for these morphological alterations and does not reduce salivation significantly \[[@pone.0155214.ref037]--[@pone.0155214.ref039]\]. The association between age and xerostomia has often been related to the use of prescription drugs \[[@pone.0155214.ref040]\]. More than 500 prescription drugs, including anticholinergic, antidepressants and antihistamines, are reported to cause xerostomia \[[@pone.0155214.ref007]\]. Dosage and duration of prescription drugs used are also important factors \[[@pone.0155214.ref041], [@pone.0155214.ref042]\]. Use of prescription drugs is also related to DED symptoms. We previously reported that use of anxiolytics and antipsycotics demonstrated the strongest correlation with symptomatic dry eyes in DED patients, as assessed by the McMonnie's Dry Eye Questionnaire and OSDI \[[@pone.0155214.ref043]\]. In contrast, antihistamines were the most prevalent systemic prescription drug used in xerostomia patients in our study. This is consistent with previous reports that have showed induction of xerostomia by antihistamines \[[@pone.0155214.ref044]\].

In the current study, among the ocular signs, only meibum expressibility was significantly worse in the xerostomia patients. Meibum quality, however, was not associated with xerostomia. Poor meibum expressibility is one of the hallmarks of evaporative DED caused by meibomian gland dysfunction (MGD), which is the most common form of DED \[[@pone.0155214.ref017]\]. The sebaceous meibomian glands normally supply lipids and proteins to the outer layer of the tear film. The outer lipid layer decreases the evaporation of the water content, hence is important for tear film stability \[[@pone.0155214.ref018], [@pone.0155214.ref045]\]. The main cause of MGD is ductal orifice obstruction due to hyperkeratinization \[[@pone.0155214.ref025]\]. The prevalence of MGD increases with age and is influenced by sex \[[@pone.0155214.ref025]\]. Various endogenous and/or exogenous factors can cause gland obstruction and/or alteration in meibomian gland secretion (quantity and/or quality). Endogenous factors include dysfunction of androgens and estrogens, which regulate the meibomian glands \[[@pone.0155214.ref025]\]. Exogenous factors include topical eye medications and contact lens use \[[@pone.0155214.ref025]\]. Since meibum expressibility, but not meibum quality, was affected in patients with xerostomia in our study, patients with xerostomia may exhibit a low delivery, rather than a high delivery, type of MGD \[[@pone.0155214.ref025]\]. The subtype of MGD dysfunction in patients with xerostomia could be investigated further by meibography and *in vivo* laser confocal microscopy to detect possible gland atrophy and dropout, periglandular inflammatory cell infiltrates and periglandular fibrosis, of which the latter two are typically seen in obstructive MGD \[[@pone.0155214.ref046], [@pone.0155214.ref047]\].

Conclusion {#sec009}
==========

In the current study DED patients with xerostomia demonstrated a higher symptom load, as demonstrated by the OSDI questionnaire, and more pathological meibum expressibility. Thus, xerostomia in DED patients may be used as an anamnestic indicator of MGD, which could warrant more extensive analyses of meibomian gland function, in addition to considering evaluation for any underlying systemic disease. Future studies using meibography and *in vivo* laser confocal microscopy could shed light on defining the subtype of MGD seen in patients with xerostomia. Xerostomia is an important factor requiring consideration in the assessment of DED.

Supporting Information {#sec010}
======================

###### Patient Demographics with Symptoms and Signs.
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Click here for additional data file.
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